• Completion of 2-year follow-up of participants in Phase 3 SCUlpTOR trial of CYP-004 for osteoarthritis
• Results of the trial expected to be released in Q2 CY 2026
• CYP-004 is Cynata's Cymerus™ off-the-shelf iPSC-derived MSC product candidate for intra-articular injection

Cynata Therapeutics Limited (ASX: 'CYP', 'Cynata', or the 'Company'), a clinical-stage biotechnology company specialising in cell therapeutics, announces the completion of the final participant study visit in the Phase 3 SCUlpTOR trial of CYP-004 in patients with osteoarthritis of the knee. This formally completes the 2-year follow-up of participants in this trial. Cynata's partner, the University of Sydney, will now work to complete data monitoring and quality control activities, followed by analysis of the data. Results of the trial are expected to be released in Q2 CY 2026. Osteoarthritis is one of the world's largest chronic disease markets, affecting around 600 million people globally and is associated with an economic burden of >US$468 billion annually in the United States alone. There is no curative therapy today - care typically progresses from lifestyle change measures to anti-inflammatories and corticosteroid injections, with many patients ultimately facing invasive, costly joint-replacement surgery that is not suitable for all. CYP-004 is Cynata's Cymerus™ off-the-shelf iPSC-derived MSC product candidate for intra-articular injection. It is a targeted, intra-articular injection designed to calm joint inflammation, relieve pain and protect cartilage.